Stock Performance Overview
On May 1, 2026, Amgen Inc. (ticker symbol: AMGN) experienced a notable decline in its stock price, reflecting broader market dynamics and specific company-related news. The stock opened at $332.52 and throughout the trading session, it reached a high of $337.00 and a low of $324.63. By the market close, Amgen's stock price was $329.82, representing a decrease of $16.43 or approximately 4.75% from the previous close of $346.25. The trading volume was approximately 3.82 million shares, indicating relatively active trading compared to average volumes.
Intraday Price Movements
- Opening Price: $332.52
- Closing Price: $329.82
- Highest Price: $337.00
- Lowest Price: $324.63
- Price Change: -$16.43
- Percentage Change: -4.75%
- Volume: 3.82 million shares
The stock's decline was influenced by multiple factors, including market reactions to earnings reports and regulatory developments.
Significant News and Events
- Earnings Report: On May 1, 2026, Amgen released its first-quarter financial results, surpassing Wall Street expectations. Earnings per share (EPS) were reported at $5.15, exceeding estimates. Total quarterly revenues reached $8.6 billion, up from $8.1 billion year-over-year. Despite the strong financial performance, the stock price declined, possibly due to overall market sentiment and investor caution.
- Regulatory Challenges: The FDA disclosed scrutiny regarding Amgen's autoimmune drug, Tavneos. The agency alleged data manipulation related to the drug's approval process, raising concerns about regulatory compliance. This development likely contributed to negative investor reactions and the stock's decline.
- IRS Tax Dispute: Amgen is engaged in an ongoing tax dispute with the IRS, which is seeking recovery of additional taxes totaling $10.7 billion. The legal challenge poses potential risks to the company’s financial stability and investor confidence.
- Analyst Ratings: Following the events of the day, analysts have issued mixed ratings on Amgen. While some maintain a positive outlook driven by robust product sales growth, others have expressed caution due to regulatory and tax uncertainties.
- Market Context: The broader market on May 1, 2026, was volatile, especially within the technology and healthcare sectors. The Nasdaq Composite index experienced declines as investors favored companies with immediate profitability, impacting Amgen’s stock performance amid cautious sentiment.
Conclusion
Amgen Inc. faced a challenging trading day marked by a significant stock price decline on May 1, 2026. Although the company delivered strong first-quarter earnings, the positive results were overshadowed by regulatory scrutiny related to Tavneos and an ongoing substantial tax dispute with the IRS. These factors, combined with a volatile market environment, led to investor concerns and a notable drop in share value. Moving forward, Amgen’s stock performance will likely continue to be influenced by developments in regulatory matters, legal disputes, and overall market conditions.
Explore more exclusive insights at nextfin.ai.
